



New Brunswick
College of Pharmacists
Ordre des pharmaciens
du Nouveau-Brunswick

Governing the practice of pharmacy for a healthier New Brunswick
Régir l'exercice de la pharmacie pour un Nouveau-Brunswick en meilleure santé

Important Updates | Mises à jour importantes

February 3, 2022

In this issue...

1. Denosumab (Xgeva®) Administration by Community Pharmacists in Patients with Cancer
2. Pharmacies adopting use of N.B. vaccination scheduling system
3. Public Health NB notice:
 - Updated guidance on COVID-19 vaccination after Myocarditis/Pericarditis
4. National Drug Schedule updates:
 - Removing Natural Health Products
 - Final Recommendations for brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%
5. New Brunswick Pharmacy Awards - Nominate someone today.

Save the Date...

- February 9: Deadline to [apply for the February 23 sitting of the NB Jurisprudence exam](#)
- February 11: Deadline for [submissions for a member of the public to sit on on NBCP Council](#)
- March 31: Deadline for [submission of N.B. Pharmacy award nominations and scholarship and bursary applications](#)

1. Denosumab (Xgeva®) Administration by Community Pharmacists in Patients with Cancer

(This item was sent previously on January 10, 2022)

Katherine Simon is a pharmacy resident at The Moncton Hospital and is conducting a research project entitled, "*Denosumab (Xgeva®) Administration by Community Pharmacists in Patients with Cancer.*"

As part of the project, a pre-recorded educational webinar was developed to review the clinical use of bone targeted agents (BTAs) in the oncology setting and introduce a proposed practice guideline and process map for denosumab (Xgeva®) safe administration, adverse event monitoring and management by pharmacists in collaboration with ambulatory oncology clinics.

Pharmacy professionals are invited to watch the video and complete a short survey to assist with gathering valuable information.

Please note the video and the survey were provided in English only.

For complete details of the project, please [read here...](#)

2. Pharmacies adopting use of the NB vaccination scheduling system

The following standard operating procedures relate to pharmacies using the New Brunswick vaccination scheduling system. This information, sent on behalf of Public Health NB, includes screenshots demonstrating the user experience when accessing the system. [{LINK}](#)

3. Public Health NB Notice: Updated guidance on COVID-19 vaccination after Myocarditis/Pericarditis

Please see the attached memo sent on behalf of Dr. Yves A. Léger, Acting Deputy Chief Medical Officer of Health, which provides updated guidance on COVID-19 vaccination after myocarditis/pericarditis. [{LINK}](#)

4. NAPRA National Drug Schedule updates

- Removing Natural Health Products

(Published with permission from the Saskatchewan College of Pharmacy Professionals)

In accordance with its [Policy for Natural Health Products \(NHPs\)](#), the National Association of Pharmacy Regulatory Authorities (NAPRA) has progressed with the planned [removal of NHPs from the National Drug Schedules \(NDS\)](#), in the stepwise, risk-based approach initiated in 2019.

NHPs in lower-risk categories were removed in 2020, while NHPs in all other categories were removed Jan. 2, 2022, with the exception of ephedrine and pseudoephedrine, which will be removed from the NDS in January 2024. These exceptions were made in consideration of the impact of COVID-19 and the substance use crisis in Canada.

As of 2024, all products with a Natural Product Number (NPN) or Drug Identification Number-Homeopathic Medicine (DIN-HM) from Health Canada will be considered outside the scope of NAPRA's NDS.

- Final Recommendations for brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%

Recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) regarding [brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%](#) were approved by NAPRA's Board of Directors and became effective January 25, 2022.

Brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and

fatigue for adults of 18 years and older be granted Schedule III status, subject to the removal from the Prescription Drug List (PDL).

Brimonidine or its salts, except when sold as brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older will remain in Schedule I (as per the Prescription Drug List)

The National Drug Schedules will be revised accordingly once the affected substance is removed from the Prescription Drug List.

5. New Brunswick Pharmacy Awards - Nominate someone today

Celebrating our successes

The New Brunswick Pharmacy Awards are one way of applauding outstanding practice and recognizing the significant achievements made by members of our profession. Equally significant is the impact of the stories shared about the recipients and the path that led them to stand out as a leader in their profession.

Please take a few moments to review the available awards for 2022
<https://www.nbpharmacists.ca/site/awards>.

As you read through the criteria, I'm sure a few names will come to mind as more than deserving of the recognition. Please submit a nomination for 2022 by March 31st.

NEW BRUNSWICK COLLEGE OF PHARMACISTS | ORDRE DES PHARMACIENS DU
NOUVEAU-BRUNSWICK
686 boul. St. George Blvd., Suite/bureau 200 Moncton, N.-B. E1E 2C6
Tel: (506) 857-8957
Toll Free/ Sans frais : 1-800-463-4434
info@nbpharmacists.ca www.nbpharmacists.ca